Voyager Therapeutics Stock Is Waking Up Before a Make-or-Break Tau Window
Voyager Therapeutics edged higher in late trading ahead of Wednesday’s regular Nasdaq session, with investors again focused on whether the company’s Alzheimer’s pipeline can move from lab data into human studies this year. Nasdaq’s regular session opens at 9:30 a.m. Eastern time, so the early price action was still thin pre-market/overnight trading, where prices can move on limited volume. That matters now because Voyager is approaching the part of the biotech calendar that can reset expectations. The company has said its investigational new drug, or IND, process for VY1706 is on track in the second quarter; an IND is the request that allows a company to begin U.S. human testing.